Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2023 ∙ Liu, Y. Kuang, K.

Predictors of COVID-19 vaccination hesitancy in China: a meta-analysis

  • Western Pacific
  • China
  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Kigongo, E. Kabunga, A. Tumwesigye, R. Musinguzi, M. Izaruku, R. Acup, W.

Prevalence and predictors of COVID-19 vaccination hesitancy among healthcare workers in Sub-Saharan Africa: A systematic review and meta-analysis

  • Africa
  • Healthcare workers
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Clerici, Bianca Scavone, Mariangela Birocchi, Simone Aloise, Chiara Peroni, Benedetta Negrini, Alessandra Ghali, Claudia Casazza, Giovanni Podda, Gian Marco

Prevalence of anti-platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines-A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Alimoradi, Z. Sallam, M. Jafari, E. Potenza, M. N. Pakpour, A. H.

Prevalence of COVID-19 vaccine acceptance among migrant and refugee groups: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ McKinley, C. J. Limbu, Y.

Promoter or barrier? Assessing how social media predicts Covid-19 vaccine acceptance and hesitancy: A systematic review of primary series and booster vaccine investigations

  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Rahman, M. O. Kamigaki, T. Thandar, M. M. Haruyama, R. Yan, F. Shibamura-Fujiogi, M. Khin Maung Soe, J. Islam, M. R. Yoneoka, D. Miyahara, R. Ota, E. Suzuki, M.

Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Watanabe, A. Iwagami, M. Yasuhara, J. Takagi, H. Kuno, T.

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Bobrovitz, N. Ware, H. Ma, X. Li, Z. Hosseini, R. Cao, C. Selemon, A. Whelan, M. Premji, Z. Issa, H. Cheng, B. Abu Raddad, L. J. Buckeridge, D. L. Van Kerkhove, M. D. Piechotta, V. Higdon, M. M. Wilder-Smith, A. Bergeri, I. Feikin, D. R. Arora, R. K. Patel, M. K. Subissi, L.

Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Dinga, J. N. Kabakama, S. Njimoh, D. L. Chia, J. E. Morhason-Bello, I. Lumu, I.

Quantitative Synthesis of Factors Associated with COVID-19 Vaccine Acceptance and Vaccine Hesitancy in 185 Countries

  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Xu, S. Li, J. Wang, H. Wang, F. Yin, Z. Wang, Z.

Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
Loading...